Organon & Co. (OGN)
| Previous close | 30.32 |
| Open | 30.15 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 29.95 - 30.43 |
| 52-week range | 22.88 - 39.47 |
| Volume | |
| Avg. volume | 2,013,963 |
| Market cap | 7.697B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 7.72 |
| EPS (TTM) | 3.92 |
| Earnings date | 03 Nov 2022 |
| Forward dividend & yield | 1.12 (3.66%) |
| Ex-dividend date | 10 Nov 2022 |
| 1y target est | 33.38 |
- Business Wire
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J., January 05, 2023--Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
- Business Wire
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
- GlobeNewswire
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-LBT); License Agreement with Organon to Commercialize XACIATO™; Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study; Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 2023 Anticipated Milestones Include: XACIATO First
